Glenmark responds to DCGI letter seeking clarification on Fabiflu

In response to the DCGI letter seeking clarification on FabiFlu, Glenmark Pharmaceuticals Ltd, a research-led, integrated global pharmaceutical company, has responded back. Please click the link below, to access the response letter.

Mumbai (Maharashtra) [India] July 21 (ANI/PRNewswire): In response to the DCGI letter seeking clarification on FabiFlu, Glenmark Pharmaceuticals Ltd, a research-led, integrated global pharmaceutical company, has responded back. Please click the link below, to access the response letter.

PDF: https://mma.prnewswire.com/media/1217258/Glenmark_Response_DCGI.pdf

This story is provided by PRNewswire. ANI will not be responsible in any way for the content of this article. (ANI/PRNewswire)

(This story has not been edited by Devdiscourse staff and is auto-generated from a syndicated feed.)